Business Context and Reporting Period
This Form 8-K filing by Aileron Therapeutics, Inc. (trading symbol: ALRN) was submitted on July 15, 2019, reporting an event that occurred on July 12, 2019. The company is an emerging growth company incorporated in Delaware with principal executive offices in Watertown, MA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a regulatory compliance issue regarding the company's stock price.
Material Changes
On July 12, 2019, the company received a deficiency letter from the Nasdaq Listing Qualifications Department. The notification stated that for the last 30 consecutive business days, the bid price for the company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Global Market (Nasdaq Listing Rule 5450(a)(1)).
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted an initial 180-calendar-day compliance period, ending on January 8, 2020, to regain compliance.
- Regaining Compliance: To cure the deficiency, the stock must close at $1.00 or more per share for a minimum of 10 consecutive business days before the compliance date.
- Alternative Options: If the company fails to regain compliance by the deadline, it may be eligible for an additional 180-day period if it transfers its listing to the Nasdaq Capital Market, provided it meets other listing standards and pays an application fee.
- Delisting Risk: If the company fails to regain compliance and is not eligible for an additional period, the stock may be delisted. The company may appeal such a determination to a Nasdaq Listing Qualifications Panel.
- Management Action: Management intends to monitor the stock price and may consider a reverse stock split to regain compliance, though there is no assurance of success.
Investor Verification Checklist
- Verify the current closing bid price of ALRN common stock to assess proximity to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or transfer to the Nasdaq Capital Market.
- Review the company's cash position in other filings (e.g., 10-Q or 10-K) to determine if it has sufficient liquidity to fund operations while addressing the listing deficiency.
- Check for any subsequent 8-K filings regarding the outcome of the compliance period or appeals to the Nasdaq Listing Qualifications Panel.